BioSpace News Archive

Aptevo Therapeutics Inc. today reported financial results for the third quarter ended September 30, 2020, and provided a business update.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September 30, 2020 and provided a business update. Logo

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to a proposed underwritten public offering

Therapeutic cell pioneer Trailhead Biosystems raises Series A funding for development of specialized human cells Financing will expand the company’s High Dimensional Design of Experiments platform (HD-DoE), support the generation of multiple specialized human cells with therapeutic properties and their pilot scale manufacturing

World Leader in Fibroblast Technology Advances Intellectual Property Position with their 250th Patent Filed Today

Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today novel data supporting utilization of the Company’s NanoStilbene™ product for enhancement of cancer immunotherapy clinical trials.

Ozone is a natural gas composed of three atoms of oxygen and is Scientifically Proven to Kill SARS Coronavirus and Influenza; Interest is Sparked in its Ability to Combat COVID-19

JDRF Canada, the leading organization funding type 1 diabetes research, is marking National Diabetes Awareness Month by honouring the power and resilience of the T1D community with the “Dear Type 1” campaign.

Monteris Medical announced today the publication of results from a multicenter clinical study with its NeuroBlate® System for the treatment of drug resistant epilepsy have been published in the peer-reviewed journal Epilepsy Research. The paper describes data from the LAANTERN prospective multicenter registry, sponsored by

New additions provide genomics researchers with improved extraction methods for ultra HMW DNA, with reduced time and increased purity, from a wide variety of biological samples